Released On: December 31, 2023
Expires On: December 31, 2024
This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC)
and Catamount Medical Education.
This activity is supported by an independent educational grant from Genentech, A Member of the Roche Group.
Target Audience
This activity is intended for neurologists, radiologists, primary care clinicians, advanced practice clinicians, nurses, and other clinicians who are part of the collaborative team managing care for patients with MS.
Learning Objectives
At the conclusion of this activity, participants should be better able to:
- Discuss the consensus recommendations for the use of MRI in the diagnosis and prognosis of MS
- Review recommendations for follow-up monitoring of disease activity, effectiveness of disease modifying treatment, and safety monitoring
- Review key recommendations and changes featured in the MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with MS
- Employ best practices for the integration of the MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with MS into interdisciplinary, team-based care in clinical practice
Faculty
David K.B. Li, MD, FRCPC
Professor Emeritus of Radiology & Associate Member Medicine (Neurology)
Emeritus Director UBC MS/MRI Research Group
Associate Director, NARCRMS (North American Registry for Care and Research in MS)
University of British Columbia
Anthony Traboulsee, MD, FRCPC
Professor, University of British Columbia Faculty of Medicine (Neurology)
MS Society of Canada Research Chair
Accreditation
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit Designation
Physician
The CMSC designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
The CMSC designates this activity for a maximum of 1.0 nursing continuing professional development (NCPD) credit (none in the area of pharmacology).
Pharmacists
This knowledge-based activity, UAN JA4008165-9999-23-029-H01-P qualifies for 1.0 contact hours (.10 CEUs) of continuing pharmacy education credit.
Interprofessional Continuing Education
This activity was planned by and for the health care team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
All other health care professionals completing this course will be issued a statement of participation.
Faculty Disclosures
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
David K.B. Li, MD, FRCPC
Consulting/Advisor/Speaker Fees: Biogen, Genzyme, Novartis Pharmaceuticals Corporation, Sanofi.
Anthony Traboulsee, MD, FRCPC
Consulting/Advisor/Speaker Fees: Biogen, EMD Serono, Novartis Pharmaceuticals Corporation, Roche, Sanofi.
Activity Staff Disclosures
June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP, served as planners and reviewers and have disclosed no relevant financial relationships.
All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at The Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.
The planners, reviewers, editors, staff, CE committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.
Contact Information
For questions about this activity, please contact Catamount Medical Education at [email protected].